SURMOUNT-5: what the head-to-head trial found
Tirzepatide produced a larger average weight reduction than the studied semaglutide regimen. The population, doses and analysis define how far that finding can travel.
The evidence
Read the head-to-head evidence, understand the limitations and compare the practical details of continuing care.
Advertising disclosure: CoreAge Rx is our featured commercial partner and appears first. Placement is promotional; it is not a clinical superiority ranking. How we are funded
How tirzepatide and semaglutide differ
The medicines act on related pathways, but the molecule, finished product, indication and delivery format all matter.
Side effects and safety: what the comparison can tell you
Both medicines have clinically important risks. Trial averages and descriptive discontinuation rates cannot replace an individual safety review.
Pills, pens and vials: compare the actual format
Delivery format changes the practical routine and instructions. It does not, by itself, establish the medicine’s approval status or clinical suitability.
Approved and compounded GLP-1 products: keep the distinction
A shared ingredient name does not establish the same finished medicine, approval status or clinical evidence.
Comparing the full cost of tirzepatide and semaglutide
The meaningful number includes the medicine, clinical care, billing period, dose and program conditions.
Questions to take to a GLP-1 consultation
Discuss the treatment goal, medical history, exact product and continuing-care plan before choosing an ingredient from a comparison chart.
Reading weight-loss numbers without overinterpreting them
Percentages, percentage points, responder rates and confidence intervals describe different things. A comparison is clearer when the denominator stays visible.
Changing GLP-1 providers: the questions before a transfer
How to compare records, prescriptions, pharmacy arrangements and costs without treating a commercial transfer offer as a dosing plan.
Provider outcome charts versus medication trials
Why self-reported member results, engagement statistics and randomized drug trials answer different questions.